Paul B. Fisher

Paul B. Fisher is a prominent figure in cancer research and the co-founder of InterLeukin Combinatorial Therapies, Inc. (ILCT), a Richmond-based startup company.12 He holds several distinguished positions:

Academic Roles

• Professor and Thelma Newmeyer Corman Chair in Oncology at Virginia Commonwealth University (VCU)3
• Director of the VCU Institute of Molecular Medicine (VIMM)2
• Professor in the Department of Human and Molecular Genetics at VCU3

Research Focus

Dr. Fisher's laboratory focuses on understanding the molecular and biochemical basis of cancer etiology and progression.4 His work has led to significant breakthroughs in cancer research:

• Discovery of the mda-7/IL-24 protein, which has potential in targeting metastatic cancers1
• Development of a genetically modified virus that selectively infects cancer cells1
• Identification of small molecule drugs that destroy tumor cells and prevent metastasis in combination with chemotherapy in preclinical studies5

Funding and Recognition

Dr. Fisher's research has received substantial support and recognition:

• Recipient of over $1.25 million in total research funding from the National Foundation for Cancer Research (NFCR) since 20081
• His project was awarded a $700,000 grant from Virginia Catalyst to advance lead cancer drug candidates1

Entrepreneurial Ventures

As co-founder of ILCT, Dr. Fisher is working to commercialize and bring to patients novel therapeutics targeting metastatic cancers, including glioblastoma.12 The company was initially funded with $750,000 and is poised to translate his laboratory findings into potential lifesaving cancer treatments.6

Dr. Fisher's work represents a significant contribution to the field of cancer research, with potential to revolutionize treatment options for aggressive forms of cancer like glioblastoma.